Zevra Therapeutics, Inc. Accounts Payable and Accrued Liabilities, Current
Zevra Therapeutics, Inc. (ZVRA) had Accounts Payable and Accrued Liabilities, Current of $13.96 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent · last filed 2026-08-05
- 2026-06-30: Accounts Payable and Accrued Liabilities, Current $13.96M.
- 2026-03-31: Accounts Payable and Accrued Liabilities, Current $11.69M.
- 2025-12-31: Accounts Payable and Accrued Liabilities, Current $11.60M.
- 2025-09-30: Accounts Payable and Accrued Liabilities, Current $11.07M.
| Period end | Accounts Payable and Accrued Liabilities, Current | Accounts Payable and Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $13.96M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $11.69M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $11.60M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $11.07M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $15.84M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $17.82M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $25.46M 10-K · filed 2026-03-09 | |
| 2024-09-30 | $24.46M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $20.45M 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $22.79M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $28.40M 10-K · filed 2025-03-12 | |
| 2023-09-30 | $13.08M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $10.51M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $10.10M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $6.17M 10-K · filed 2024-04-01 | |
| 2022-09-30 | $4.28M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $3.60M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $2.58M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $3.04M 10-K · filed 2023-03-07 | |
| 2021-09-30 | $2.08M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $2.97M 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $2.85M 10-Q · filed 2021-05-14 | |
| 2020-12-31 | $6.65M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $4.35M 10-Q · filed 2020-10-30 | |
| 2020-06-30 | $4.73M 10-Q · filed 2020-08-12 | |
| 2020-03-31 | $6.42M 10-Q · filed 2020-05-13 | |
| 2019-12-31 | $4.91M 10-K · filed 2021-03-12 | |
| 2019-09-30 | $3.10M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $7.86M 10-Q · filed 2019-08-13 | |
| 2019-03-31 | $8.18M 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $8.34M 10-K · filed 2020-02-28 | |
| 2018-09-30 | $14.68M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $13.97M 10-Q · filed 2018-08-10 | |
| 2018-03-31 | $10.18M 10-Q · filed 2018-05-11 | |
| 2017-12-31 | $7.88M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $6.36M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $6.30M 10-Q · filed 2017-08-10 | |
| 2017-03-31 | $4.58M 10-Q · filed 2017-05-22 | |
| 2016-12-31 | $6.44M 10-K · filed 2018-03-30 | |
| 2016-09-30 | $5.60M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $5.36M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $4.18M 10-Q · filed 2016-05-13 | |
| 2015-12-31 | $4.91M 10-K · filed 2017-03-10 | |
| 2015-09-30 | $4.03M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $4.88M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | $4.00M 10-Q · filed 2015-05-29 | |
| 2014-12-31 | $3.10M 10-K · filed 2016-03-16 | $3.90M 10-Q · filed 2015-05-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |